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Abstract
The spread of multidrug-resistant bacteria is an ever-growing concern, particularly among Gram-negative bacteria
because of their intrinsic resistance and how quickly they acquire and spread new resistance mechanisms. Treating
infections caused by Gram-negative bacteria is a challenge for medical practitioners and increases patient mortality
and cost of care globally. This vulnerability, along with strategies to tackle antimicrobial resistance development,
prompts the development of new antibiotic agents and exploration of alternative treatment options. This article
summarises the new antibiotics that have recently been approved for Gram-negative bacterial infections, looks down
the pipeline at promising agents currently in phase I, II, or III clinical trials, and introduces new alternative avenues
that show potential in combating multidrug-resistant Gram-negative bacteria. © 2019 Elsevier Ltd
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Use of bacteriophages to target certain bacteria was a very early idea that has recently undergone a renaissance.
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